



HEALTHCARE EXECUTIVE ALLIANCE  
SPECIAL EDITION ON E-LEARNING

# Money Talks

- COSTS, COSTS, COSTS! WHO PAYS IN HEALTHCARE?, *C. MCCAHAN*
- HOSPITAL FINANCE, *M. NOPPEN*
- TRANSFORMING COMMISSIONING TO DO MORE WITH LESS, *C. COTTON*
- MAKING AFFORDABLE HEALTHCARE PROFITABLE, *A. MIR*
- PRESENTING A CASE: FINANCING IT PROJECTS, *M. HASIB ET AL.*
- NATIONAL TELEHEALTH CAN SAVE MONEY AND IMPROVE HEALTH, *H.E. HENRIKSEN*
- FINANCE TECHNOLOGY BLOCKCHAIN IN HEALTHCARE IT SECURITY, *T. LAURENCE*
- FRAUD IN HEALTHCARE, *S. PECK & L. MCKENNA*

ANN MARIE O'GRADY: NEW  
HEALTHMANAGEMENT.ORG EXEC  
EDITOR-IN-CHIEF

MATURITY MAKES GREAT LEADERS,  
*T. VELDSMAN*

WHEN A CYBERCRIME TAKES  
PLACE – WHO'S TO BLAME?  
*A.K. GUPTA & M. HASIB*

DIGITAL HEALTH HUB AT YOUR  
SERVICE, *J. SINIPURO*

ENTERPRISE VIEWERS,  
*D. HIRSCHORN*

CLOUD-BASED IT PLATFORM FOR

CLINICAL TRIALS IN ONCOLOGY,  
*D. CAMELLA ET AL.*

RAD-AID INTERNATIONAL AND  
GLOBAL HEALTH RADIOLOGY,  
*M.P. CULP, J.S. HARFORD,  
S.G. JORDAN*

RADIOLOGY EDUCATION GOES  
MOBILE, *E. KOTTER*

CONTRAST-ENHANCED MRI,  
*S. HEYWANG-KÖBRUNNER*

RADIOPROTECTION IN CHEST CT,  
*R. ALMEIDA ET AL.*

NEW US DEVICE USES 3D

PRINTING TECHNOLOGY, *C-D OHL*

3D PRINTED KIDNEY PHANTOMS  
WILL OPTIMISE RADIATION DOSE,  
*J. TRAN-GIA*

PRECLINICAL IMAGING IN THE ERA OF  
PERSONALISED MEDICINE, *A. GRECO*

INDUCED PLURIPOTENT STEM CELLS  
IN CARDIOVASCULAR PRECISION  
MEDICINE, *M. CHANDY, J.C. WU*

AMERICAN COLLEGE OF  
CARDIOLOGY 2017 MEETING,  
*T. KAIER*

TRUMP ON DRUGS, *J.W. SALMON*



# Cloud-Based IT Platform for Clinical Trials in Oncology

Computerisation of data collection in a multicentre clinical trial allows fast and easy conduct of the study. Cloud computing is a viable solution for storing patient data in virtual archives accessible by different hospitals. The adoption of an IT platform for centralised review of images and clinical reports in trials saves resources and time.



**Davide Caramella**

Professor Diagnostic and Interventional Radiology University of Pisa Pisa, Italy

Editorial Board Member, HealthManagement

davide.caramella@med.unipi.it



**Ruggero Dell'Osso**

Computer Scientist Diagnostic and Interventional Radiology University of Pisa

ruggero.dellosso@med.unipi.it

**Giuseppe Imbarlina**

Diagnostic and Interventional Radiology University of Pisa

giuseppe.imbarlina@for.unipi.it

**Elisa Troiano**

Diagnostic and Interventional Radiology University of Pisa

troiano.elisa@gmail.com

Multicentre clinical trials allow rapid collection of data involving great numbers of patients, and let researchers gain specialist advice from international experts. In multicentre clinical trials it is common practice to have clinical auditors at a central radiology centre who perform secondary reading of patient data produced by various radiological centres. CDs or DVDs of radiological images and paper documents with tumour size measurements, according to the Response Evaluation Criteria in Solid Tumours (RECIST) Image Transmittal Form (ITF) (Eisenhauer et al. 2009), are both sent by courier to the central radiology centre for secondary reading. This process is time- and resource-intensive, as it requires individual documents to be physically sent. As the number of patients needing review grows, the burden and delay increases

In order to improve the process, the research team at the radiology department in the University of Pisa hospital has developed an IT platform built on a cloud-based virtual server for a more rapid secondary review of images from multi-centre locations.

## Cloud Computing

In oncological trials periodic follow-ups by means of CT or MRI are performed. These imaging modalities require substantial digital storage. Although the number of patients in the clinical trial is defined, it is not possible to determine in advance the total number of follow-up procedures that each patient may undergo; consequently the overall storage requirement cannot be predicted. In this context, the adoption of cloud technology has the benefit of being able to adapt dynamically to the needs of the trial in terms of storage.

Traditionally, a local server was employed for the management of centralised reading. This method has several preliminary requirements:

1. Establish the extent of storage resources
2. Acquire computing resources (CPU, RAM) suitable for replying to requests within a reasonable time
3. Provide backup and recovery mechanisms in the event of failure

4. Dedicated human resources for management of the system at low-level (hardware, operating system, networking, backup), intermediate level (applications and archives management, interactions between autonomous systems, security) and high level (use of applications and production tools for interpretation and processing of information)

As opposed to the traditional approach, the proposed cloud technology allows, depending on requirements, for more adaptive storage resources, and it does not require the use of dedicated human resources for the management of the physical system, as the cloud service provider undertakes this task.

“ADOPTION OF CLOUD TECHNOLOGY FOR MANAGEMENT OF CENTRALISED READING IN A CANCER CLINICAL TRIAL HAS SHOWN CRUCIAL ADVANTAGE”




Figure 1

Figure 2

Figure 3




Figure 4

### IT Platform

The main issues that need to be considered in designing a platform for a fully electronic central review system are:

1. The choice of a communication protocol for uploading images on the platform. The most frequently used protocols are File Transfer Protocol (FTP) and Hypertext Transfer Protocol (HTTP)
2. The choice of a Picture Archiving and Communication System (PACS) for images storage
3. Choice of a Digital Imaging and Communications in Medicine (DICOM) viewer
4. Implementation of an electronic ITF
5. Implementation of security measures to ensure compliance with U.S. Food and Drug Association (FDA) 21 Code of Federal

## Case Study: *Erbix Metastatic Colorectal Cancer Strategy*

The cloud-based IT platform has been used for the management of the radiological images and their centralised reading in the clinical trial ERbitux METastatic colorectal cancer Strategy (ERMES), which was sponsored by Policlinico Agostino Gemelli ([clinicaltrials.gov/ct2/show/NCT02484833](http://clinicaltrials.gov/ct2/show/NCT02484833)). The University of Pisa Hospital plays a dual role, being both a local radiology imaging centre and the central radiology imaging centre.

The clinical trial ERMES is a multicentric, non-inferiority phase III randomised study in patients with RAS and BRAF WT metastatic colorectal cancer. They are randomised to receive first line FOLFIRI + Cetuximab until disease progression (or unacceptable toxicity), or FOLFIRI + Cetuximab for 8 cycles followed by Cetuximab alone until disease progression (or unacceptable toxicity). Planned accrual time is 50 months, initially planned to be 24 months. In total 600 patients will be randomised, 300 for each arm. The end of the trial will be the date of the last visit of the last participant in the protocol. Final analysis of the data and report writing will occur after formal declaration of the end of the trial. As a participating centre, the University of Pisa has enrolled and randomised 3 patients; only one of them is still on treatment. The others have reached progression and thus are continuing with a second-line therapy. Among the 3 patients from Pisa, the patient who best represents the typical disease progression is patient number 17-0002 who was randomised on 21/01/2016, underwent first dose of therapy on 22/01/2016 and exited the trial on 23/12/2016. Disease assessment according to RECIST 1.1 shows two target lesions and a single non-target lesion in hepatic sub-segments IV, V, VII, respectively. **Figure 4** shows that the patient achieved a 65% decrease in tumour burden after 7 months of therapy, which according to RECIST 1.1 is considered a partial response.

Regulations (CFR) Part 11 on electronic records.

**Figure 1** shows the IT platform and its main components. The platform has been installed on a virtual server within a private infrastructure-as-a-service (IaaS) cloud provided by the IT centre of the University of Pisa. The cloud-based virtual server runs the Ubuntu 14.04 operating system and is equipped with 8 CPU, 16 GB of RAM and a total of 500 GB of storage.

### **Communication protocol for images upload**

Images are uploaded to the IT platform using File Transfer Protocol (FTP) protocol, then sent to the Picture Archive and Communication System (PACS) through DICOM C-STORE transactions. Prior to uploading, each radiology imaging centre must perform anonymisation, de-identification and assignment of a patient identifier according to how it is specified in the trial protocol. De-identification and anonymisation are common strategies that are used to remove patient identifiers in electronic health record data. The use of these strategies in multicentre research studies is of paramount importance, given the need to share electronic health record data across multiple environments and institutions while safeguarding patient privacy.

“ THE PLATFORM ALLOWS  
PROMPT DATA AVAILABILITY, EASY  
IMAGE COMPARISON... ”

### **PACS and DICOM viewer**

The Dcm4chee open source PACS, backed by a MySQL database, is used for image archiving, and the web DICOM viewer, 'Oviyam' is used for image viewing. All communications between the viewer and PACS are done through the Web Access to Dicom Objects (WADO) service.

### **Electronic ITF**

The ITF is a web application that allows electronic management of all clinical information needed for centralised reading. The server side of the application is implemented in Java Enterprise Edition (EE), which leverages the GlassFish application server and can be used on any operating system with Java. The database server used by the application for data storage is the MySQL database engine, which provides different privilege levels to users based on their roles in the clinical trial. Local radiology imaging centres can upload and store measurements according to RECIST criteria for each examination uploaded on the platform. The

central radiology imaging centre can view the RECIST measurements provided by local centres and submit the results of the review. The clinical trial sponsor can view all data stored on ITF, but cannot make any database changes. A system administrator creates users and provides them with appropriate privileges. In order to ensure compliance with FDA rule 21 CFR Part 11 on electronic records, the application provides an audit trail by recording every change to the database, not only the user who made the change, but also the time and date of modification.

**Figure 2** shows the form that local radiology imaging centres fill out to submit an imaging study for centralised reading. It includes information about the patient's identifier, study date, measurements of lesions (target, non-target lesions and new), Dose Length Product (DLP) and global assessment of disease according to RECIST criteria; Complete response, Partial response, Stable disease and Progressive disease.

**Figure 3** shows the form used by the central radiology imaging centre to report the results of the review. It is in two parts. The first part is not editable and contains information provided by the local radiology imaging centre that has submitted the exam to centralised reading. The second part is used to archive the results of the review, including the global assessment of the disease discrepancies with the assessment provided by the local radiology imaging centre, and other comments.

## Security

Security is ensured through the use of user names and passwords to uniquely authenticate users and provide different privilege levels to access the ITF. A local radiology imaging centre can only create, view and edit their own data and not those of other centres. The central radiology imaging centre can display all data and insert results of the review. The sponsor can display all data, but cannot make changes to the database.

Data exchange on the internet takes place over Secure Sockets Layer (SSL) encrypted channel. This

happens for all FTP and HTTP connections. Firewall access to the DICOM viewer and PACS is only permitted to users of the central radiology imaging centre.

## Conclusion

Adoption of cloud technology for management of centralised reading in a cancer clinical trial has shown crucial advantages. Since the management of infrastructure is provided by the cloud service provider, it has allowed radiology department technical staff to exclusively devote their time to implementation of the IT platform. We have used the platform in clinical practice and verified its simplicity of use, both from the point of view of the local radiology imaging centre as uploaders of data, as well as that of the central radiology imaging centre as reviewers. Overall we have found that the platform allows prompt data availability, easy image comparison, fewer human errors and time and cost reduction, thus ensuring a more rapid secondary review. ■

## KEY POINTS



- ✓ Computerisation of data collection in a multi-centre clinical trial allows fast and easy conduct of the study
- ✓ Cloud computing is a viable solution for storing patient data in virtual archives that are accessible by different hospitals
- ✓ The adoption of an IT platform for the centralised review of images and clinical reports in cancer clinical trials results in an overall reduction of resources and time



## REFERENCES

Eisenhauer EA, Therasse P, Bogaerts J et al. (2009). New response evaluation in solid tumours: Revised RECIST guideline (version 1.1). *Eur J Cancer*, 45(2): 228-47.

European Medicines Agency (2002) ICH Harmonised tripartite guideline E6: note for guidance on good

clinical practice (PMP/ICH/135/95). London: European Medicines Agency.

United States. Food and Drug Administration (2010) Code of Federal Regulations Title 21. Food and Drugs. Chapter I. Food and Drug Administration. Subchapter

A. General. Part 11. Electronic records; Electronic signatures. 21 CFR 11. [Accessed: 7 April 2017] Available from [accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=11](https://accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=11)